top of page
Trial title:
A Phase 1-2 master protocol to study intravenous ATTR-01 in adult participants with select epithelial solid tumours under multiple sub-protocols (ATTEST) 
Trocept-One_logo_white.png

ATTEST clinical trial testing TROCEPT-01 (ATTR-01),
a novel ‘tumour-activated’ Immunotherapy for
solid cancers

AT_Trocept-cancer-drug_v3_1920px.png
The aim of this trial
ATTEST is a Phase 1 trial which is testing a new drug TROCEPT-01 (called ATTR-01in the clinic) to find out if it may work to treat different types of solid cancers. ATTR-01 is the first drug using the TROCEPT platform.
How does
Trocept_logo-design_4h.png
work?
TROCEPT-01 (ATTR-01)
is injected into a vein and finds the cancer.
1
TROCEPT-01 (ATTR-01) only enters cancer cells.
2
TROCEPT-01 (ATTR-01)
delivers the gene for a checkpoint inhibitor into tumor, causing it to make and secrete the active checkpoint inhibitor inside the tumour.

Checkpoint inhibitor released from cancer cell

3
TROCEPT-01 (ATTR-01)
only replicates in, and kills, cancer cells, turning cold tumors hot. This can boost the anti-tumour effect of the checkpoint inhibitor.

Dying cancer cell

Trocept kills cancer cells

4
TROCEPT-01 (ATTR-01)
enables a checkpoint inhibitor to be made only inside of the cancer. 
5

Checkpoint inhibitor and TROCEPT only build up in the cancer

Single_Cell_Gradient_8f_1920x1080.jpg
Cancer types included in the ATTEST clinical trial:
1
2
3
4
5
6
Head and neck cancer
Non-Small cell Lung cancer
Pancreatic cancer
Cholangiocarcinoma
Bladder cancer
Endometrial cancer
Cancer types included in Accession Therapeutics first ATTEST clinical trial testing TROCEPT-01 (ATTR-01)
1
2
3
4
5
6
AT_Trocept-trial-patient_v2f.png
ATTEST - UK registered clinical study
Who is the ATTEST trial sponsor?
Accession Therapeutics Limited (UK)

Where is the ATTEST trial registered?
​You'll find us on ISRCTN 
bottom of page